{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-039201","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.360848+00:00","generated_at":"2026-06-11T13:55:42.151067+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocuphire Pharma Q2 net loss $5.0M ($0.24/sh); cash $40M, Lincoln Park $50M financing","bullets":["Cash and cash equivalents of $40.0M as of June 30, 2023; no debt; operations funded into 2025.","License revenue of $3.7M in Q2 2023 vs $0 in prior-year period; net loss $5.0M vs $4.9M.","Nyxol PDUFA date September 28, 2023; FDA approval would trigger a $10M milestone payment.","End-of-Phase 2 meeting with FDA for oral APX3330 in diabetic retinopathy scheduled for Q4 2023.","Entered common stock purchase agreement with Lincoln Park for up to $50M over 30 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-039201","json":"https://secwatch.observer/filing/0001140361-23-039201.json","markdown":"https://secwatch.observer/filing/0001140361-23-039201.md","text":"https://secwatch.observer/filing/0001140361-23-039201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123039201/0001140361-23-039201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123039201/brhc20057386_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:55:42.151067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d9691e05421778d6653b82af74cc4825e43eb9a","claim":"Opus Genetics, Inc. reported second quarter ended June 30, 2023 results: revenue approximately $40.0 million, net income Net loss for the three and six months e.","evidence_excerpt":"Results for Second Quarter 2023 and Provides Corporate Update End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR) Cash Balance of $40 Million Expected to Fund Operations into 2025 Nyxol RM PDUFA date September 28, 2023; Approval would trigger $10 million milestone payment to Ocuphire Common Share Purchase Agreement","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123039201/0001140361-23-039201-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"approximately $40.0 million"},{"label":"Net income","value":"Net loss for the three and six months e"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5a303830df1da9223fb8bd9cb8ac7394b0f6e5d2","claim":"Opus Genetics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $50,000,000 (effective 2023-08-10).","evidence_excerpt":"On August 10, 2023, Ocuphire Pharma, Inc. (the “Company”) entered into a common stock purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right, but not the obligation, to sell to Lincoln Park up to $50,000,000 of shares of the Company’s common stock (the “Purchase Shares”) from time to time over the 30-month term of the Purchase Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123039201/0001140361-23-039201-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lincoln Park Capital Fund, LLC"},{"label":"Value","value":"up to $50,000,000"},{"label":"Effective","value":"2023-08-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}